Skip to content
10-K

Annual Report

GAIN THERAPEUTICS, INC GANX

0001104659-26-035188

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 28, 2026 42.24M sh
Shares Diluted FY 2025 · Dec 31, 2025 32.97M sh
Shares Diluted FY 2025 · Dec 31, 2024 22.88M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$18.47M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$18.87M
Long Term Debt FY 2025 · Dec 31, 2025 $300.08K
Long Term Debt FY 2025 · Dec 31, 2024 $328.33K
Short Term Debt FY 2025 · Dec 31, 2025 $100.87K
Short Term Debt FY 2025 · Dec 31, 2024 $110.18K
Cash And Equivalents FY 2025 · Dec 31, 2025 $20.84M
Cash And Equivalents FY 2025 · Dec 31, 2024 $10.39M
Stockholders Equity FY 2025 · Dec 31, 2025 $18.56M
Stockholders Equity FY 2025 · Dec 31, 2024 $7.34M
Stockholders Equity FY 2025 · Dec 31, 2023 $12.58M
Current Liabilities FY 2025 · Dec 31, 2025 $3.35M
Current Liabilities FY 2025 · Dec 31, 2024 $3.91M
Total Liabilities FY 2025 · Dec 31, 2025 $4.25M
Total Liabilities FY 2025 · Dec 31, 2024 $4.78M
Current Assets FY 2025 · Dec 31, 2025 $22.24M
Current Assets FY 2025 · Dec 31, 2024 $11.6M
Total Assets FY 2025 · Dec 31, 2025 $22.82M
Total Assets FY 2025 · Dec 31, 2024 $12.12M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.61
Eps Diluted FY 2025 · Dec 31, 2024 −$0.89
Eps Basic FY 2025 · Dec 31, 2025 −$0.61
Eps Basic FY 2025 · Dec 31, 2024 −$0.89
Sga Expense FY 2025 · Dec 31, 2025 $8.5M
Sga Expense FY 2025 · Dec 31, 2024 $9.56M
Rd Expense FY 2025 · Dec 31, 2025 $10.21M
Rd Expense FY 2025 · Dec 31, 2024 $10.79M
Net Income FY 2025 · Dec 31, 2025 −$20.16M
Net Income FY 2025 · Dec 31, 2024 −$20.41M
Operating Income FY 2025 · Dec 31, 2025 −$18.71M
Operating Income FY 2025 · Dec 31, 2024 −$20.35M